Table 1.
Definitions of phases of persistent HBV infection.
Table 2.
Clinical details of the studied patients.
Figure 1.
Comparison of intrahepatic (IH) HBV cccDNA levels among patients with different clinical presentations.
The horizontal lines illustrate the 25th, 50th, and 75th percentiles of the cccDNA levels. Symbols * and ** represent P value less than 0.01 and 0.05, respectively. AHB, acute hepatitis B; CHB, chronic HBV infection; IT, immune-tolerant; IC, immune-clearance; LR, low-replicative; ENH, HBeAg-negative hepatitis.
Figure 2.
Quantitation of serum HBsAg for 120 HBV-infected patients with different clinical presentations.
The distribution of serum HBsAg level across the study population (A). Comparison of serum HBsAg levels among patients with different clinical presentations (B). Symbol ** represent P value less than 0.01.
Figure 3.
Analysis of correlation between intrahepatic (IH) HBV cccDNA and serum HBV markers for 19 patients with acute hepatitis B.
Correlation between intrahepatic HBV cccDNA level and serum HBsAg level (A). Correlation between intrahepatic HBV cccDNA level and serum HBV DNA level (B).
Figure 4.
Overall analysis of correlation between intrahepatic (IH) HBV cccDNA and serum HBV markers across 101 patients with chronic HBV infection.
Correlation between IH cccDNA level and serum HBsAg level (A). Correlation between IH cccDNA level and serum HBV DNA level (B).
Figure 5.
Phase-categorized analysis of correlation between intrahepatic (IH) HBV cccDNA level and serum HBsAg level for patients with chronic HBV infection.
Analysis for 10 patients in immune-tolerant phase (A). Analysis for 59 patients in immune-clearance phase (B). Analysis for 8 patients in low-replicative phase (C). Analysis for 24 patients in HBeAg-negative hepatitis phase (D).
Figure 6.
Phase-categorized analysis of correlation between intrahepatic (IH) HBV cccDNA level and serum HBV DNA level for patients with chronic HBV infection in different phases.
Analysis for 10 patients in immune-tolerant phase (A). Analysis for 59 patients in immune-clearance phase (B). Analysis for 8 patients in low-replicative phase (C). Analysis for 24 patients in HBeAg-negative hepatitis phase (D).
Figure 7.
Monitoring of serum HBsAg and HBV DNA levels in patients with acute hepatitis B.
Dynamical change of serum HBsAg level (A). Dynamical change of serum HBV DNA level (B). Association of reductions between serum HBsAg level and HBV DNA level 14 days post patient admission (C).
Figure 8.
Relationship of HBV replicative efficiency with histological activitiesin CHB-IC patients.
Correlation between HBV replicative efficiency and histological grade of active inflammation (A). Correlation between HBV replicative efficiency and histological stage of fibrosis(B).